Greater Boston
Department head for antibody-drug conjugations targeting cancer. Leading scientists, projects, and portfolio in the ADC field: - Antibody-drug conjugations, analysis, and characterization - New linker technology, including site-specific conjugations and novel payloads - Internal drug discovery projects - Partnered and collaborative discovery projects
Team leader for Infection Biophysics group and for In Vitro Virology. Project leader for antibiotic drug discovery: led thymidylate kinase project from target ID to late lead optimization. Project management: supporting and writing NDA filing for AVYCAZ (ceftazidime-avibactam, Phase III) by contracting and managing internal and external scientific studies. Led “line-of-sight” team in developing clinical, regulatory, and commercial cases for Infection early development projects. Function lead for global data processing and storage initiatives. Externalization: managing collaborative discovery projects (BioFocus, UK, and ETC, Singapore), and CRO scientists for internal projects. Due diligence team for Infection external acquisitions. Bioscience lead generation: led multidisciplinary group in developing new target-based screening strategies through assay development and screening. Core member Infection Lead Generation, responsible for new projects, strategy, and pipeline delivery. Biochemical contributions to early and late-stage discovery projects: chemical and kinetic enzyme reaction mechanisms, protein biophysical characterization (ITC), competitive binding assays, high-throughput screening assay development and delivery, project database and cascade management.